Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA).

29 de maio de 2026 atualizado por: Serene Sleep, Inc.

A Prospective, Non-Randomized, Multi-Center, Two-Arm Study Evaluating the Serene Sleep Palatal Implant System

This clinical investigation is a prospective, non-randomized, parallel-group clinical investigation conducted at two (2) investigative sites. Study participants will be assigned to one of two study groups, snoring and obstructive sleep apnea, in a parallel manner based on predefined eligibility criteria.

The study aims to evaluate and compare outcomes between the two groups under investigation. The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.

The design allows for the concurrent enrollment and follow-up of participants in both arms, enabling direct observation of differences in safety across the groups over time.

Visão geral do estudo

Status

Ainda não está recrutando

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

26

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • California
      • San Francisco, California, Estados Unidos, 94102
        • Aesthetic Surgery Center
        • Contato:
        • Investigador principal:
          • Michael R Macdonald, MD
    • Georgia
      • Evans, Georgia, Estados Unidos, 30907
        • Augusta ENT
        • Contato:
        • Investigador principal:
          • Jonathan P Lindman, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

INCLUSION CRITERIA

A potential participant must meet ALL the following criteria to be enrolled into this study:

  1. Participant is ≥18 years of age.
  2. Participant has Body Mass Index (BMI) less than or equal to 30 kg/m²
  3. Participant has a tonsil grade less than or equal to 2
  4. Participant has a Friedman Tongue Position (FTP) I or II
  5. Participant is able to provide voluntary written informed consent.

For a snoring participant to be selected for the study:

  • Confirmed identification of palatal snoring

    • Investigators will utilize standard of care clinical assessment methods to confirm the presence of palatal snoring prior to enrollment. These methods may include patient-reported history, physical examination of the upper airway, and auscultation or audio recordings.
  • Confirmed elimination of potential sleep apnea diagnosis

    • If the evaluating doctor suspects that the participant may be experiencing OSA, investigators will utilize standard of care clinical assessment methods to confirm OSA.
    • A resulting AHI <5 would classify the participant as an eligible snoring subject

For an OSA participant to be selected for study:

Confirmed identification of apnea caused by palatal collapse

  • Investigators should be able to make this identification through intraoral evaluation in accordance with their standard of care
  • Confirmed mild-to-moderate classification of OSA

    • If the evaluating investigator knows or suspects that the participant may be experiencing OSA, standard of care diagnostic methods will be used as confirmation.
    • A resulting AHI between 5 and 30 would classify the participant as an eligible OSA subject.

EXCLUSION CRITERIA

A potential participant will be excluded from enrollment if ANY of the following conditions apply:

  1. A record of allergic reaction to polyethylene terephthalate (PET) / polyester
  2. An overly sensitive gag reflex
  3. Septal deviation or nasal obstruction
  4. Nasal polyps
  5. Severe seasonal allergies
  6. Soft palate length insufficient to accommodate implants
  7. Prior Diagnosis of Lingual tonsil hypertrophy
  8. Hypopharyngeal obstruction
  9. Previous pharyngeal surgery
  10. Previous upper respiratory tract cancer or radiation therapy
  11. Active respiratory tract infection
  12. Dysphagia or speech disorder
  13. Neurologic disorder
  14. Unstable psychiatric disorder
  15. Pregnant or breastfeeding
  16. History of falling asleep driving or Motor Vehicle Accident (MVA) due to sleepiness
  17. Clinical Presentation that suggests Severe OSAHS (ESS >20, participant report of choking or gasping during sleep, etc.)
  18. Marfan's Syndrome, Ehler-Danlos syndromes or other disorders of connective tissue and/or muscular tissue
  19. Other sleep disorders
  20. Other significant craniofacial anomaly
  21. Participant is participating in any of the following:

    • A study with the same or similar primary endpoint
    • Any study in which the investigator determines may interfere with the results of this study
  22. Participant is unwilling to complete all study related assessments and follow-up visits
  23. Participant is unwilling or unable to abstain from all alcohol consumption for 24 hours leading up to the intake sleep study
  24. Participant is unwilling or unable to abstain from all smoking, vaping, and/or oral tobacco products for 48 hours following the procedure
  25. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Snoring Group
Implant with the Serene Sleep Palatal Implant System
Serene Sleep Palatal Implant System
Experimental: Mild to Moderate OSA Group
Implant with the Serene Sleep Palatal Implant System
Serene Sleep Palatal Implant System

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of Participants with Implant Extrusion at 30 Days and Absence of Serious Adverse Device Effects (SADEs) [Hybrid Composite Safety Endpoint]
Prazo: From baseline to 30 days post-procedure
The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.
From baseline to 30 days post-procedure

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change is Visual Analogue Scale (VAS) Score
Prazo: From baseline to 30 days post-procedure
The change in subjective snoring severity as measured by a 10 cm Visual Analogue Scale (VAS), scored 0-10, where 0 = no snoring and 10 = extremely annoying snoring (higher scores indicate worse outcome).
From baseline to 30 days post-procedure
Change in Snoring Outcomes Survey (SOS)
Prazo: From baseline to 30 days post-procedure
The change in subjective snoring as measured by the Snoring Outcomes Survey (SOS), an 8-item validated instrument assessing intensity, duration, frequency, and impact of snoring/sleep-disordered breathing symptoms.
From baseline to 30 days post-procedure

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change in daytime Epworth Sleepiness Scale (ESS)
Prazo: From baseline to 30 days post-procedure
The change in daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS), a validated 8-item questionnaire scored 0-24, where 0 = no daytime sleepiness and 24 = severe daytime sleepiness (higher scores indicate worse outcome).
From baseline to 30 days post-procedure
Change in Apnea-Hypopnea Index (bAHI3) via Home Sleep Apnea Test
Prazo: From baseline to 30 days post-procedure
AHI Score calculated using a 3% oxygen desaturation threshold (bAHI3), collected via the Belun Sleep System HSAT device. Data will be anonymized; complete reports will be utilized as exploratory data.
From baseline to 30 days post-procedure
Change in Apnea-Hypopnea Index (bAHI4) via Home Sleep Apnea Test
Prazo: From baseline to 30 days post-procedure
AHI Score calculated using a 4% oxygen desaturation threshold (bAHI4), collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Minimum Oxygen Saturation (SpO₂) via Home Sleep Apnea Test
Prazo: From baseline to 30 days post-procedure
Minimum SpO₂ recorded during the sleep study period, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Time with Oxygen Saturation ≤90% via Home Sleep Apnea Test
Prazo: From baseline to 30 days post-procedure
Total cumulative duration during which SpO₂ was recorded at or below 90%, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Sleep Efficiency via Home Sleep Apnea Test
Prazo: From baseline to 30 days post-procedure
Sleep efficiency calculated as the proportion of time in bed spent asleep, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Total Sleep Time (TST) via Home Sleep Apnea Test
Prazo: From baseline to 30 days post-procedure
Total duration of sleep recorded during the study period, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Mean Pulse Rate via Home Sleep Apnea Test
Prazo: From baseline to 30 days post-procedure
Mean pulse rate recorded during the sleep study period, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Arrhythmia Ratio via Home Sleep Apnea Test
Prazo: From baseline to 30 days post-procedure
Ratio of arrhythmic heartbeats to total heartbeats recorded during the sleep study period, collected via the Belun Sleep System HSAT device
From baseline to 30 days post-procedure
Change in Auditory Evaluation of Snoring
Prazo: From baseline to 30 days post-procedure

Outcome 6a: "Change in Objective Snoring Volume (decibels) via Audio Recording" - the change in mean snoring volume (dB) captured by at-home overnight audio recording.

Outcome 6b: "Change in Objective Snoring Frequency (Hz) via Audio Recording" - the change in dominant snoring frequency captured by at-home overnight audio recording.

From baseline to 30 days post-procedure
Proportion of Participants with Implant Migration or Trend Toward Extrusion as Assessed by Oropharyngeal Examination at 30 Days
Prazo: Date of procedure to 30 days post-implant
At each post-procedure visit (Day 7 and Day 30), the physician will conduct a standardized oropharyngeal examination to evaluate and document whether implant location has changed from the original placement position or is trending toward extrusion. Findings will be recorded as a binary outcome (yes/no change in location) and summarized descriptively.
Date of procedure to 30 days post-implant

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de junho de 2026

Conclusão Primária (Estimado)

1 de setembro de 2026

Conclusão do estudo (Estimado)

1 de outubro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

3 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de maio de 2026

Primeira postagem (Real)

29 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Palatal Implant System

3
Se inscrever